Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with sintilimab for advanced refractory non-small cell lung cancer
ChiCTR2000034888Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat and sintilimab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Progression-free survival, Maximum tolerated dose and 2 more. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
tucidinostatsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000034888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034888.